Table 3.
Cost-effectiveness results over the 12-month trial period (costs in AU$)
| Trial–based 12-mo results | Prophylactic Ig, mean (95% CI) |
Prophylactic antibiotics, mean (95% CI) |
Difference, mean (95% CI) |
|---|---|---|---|
| Total costs per person | $46 953 (38 474-55 431) | $17 813 (9 345-26 280) | $29 140 (15 941-42 340) |
| QALY (unadjusted) per person | 0.792 (0.687-0.897) | 0.864 (0.820-0.910) | –0.072 (–0.167 to 0.023) |
| Serious infections per person | 0.24 (0.04-0.44) | 0.50 (0.17-0.82) | –0.26 (–0.74 to 0.21) |
| All infections per person | 2.76 (1.78-3.75) | 2.00 (1.38-2.62) | 0.76 (–0.33 to 1.86) |
| ICER (cost/QALY) | Ig dominated (higher costs, lower QALYs) | ||
| ICER (cost/serious infection) | $111 262 per serious infection prevented | ||
| ICER (cost/any infection) | Ig dominated (higher costs, more infections) | ||
| Incremental net benefit | –$32 740 (–45 678 to –19 958) | ||
Utilities were derived from EQ-5D-5L trial data. All costs are in AU$ for the year 2023.
Serious infections are grade ≥3, as confirmed by an independent committee.
We do not report the 95% CI around a negative ICER because it can be misleading. A negative ICER can either represent a very cost-effective result (lower costs, better health outcomes) or a not cost-effective result (higher costs, worse health outcomes). Please see a visual presentation of the 95% CI in Figure 2, which allows an easier interpretation.